2.53
0.04 (1.61%)
| Previous Close | 2.49 |
| Open | 2.59 |
| Volume | 1,954,653 |
| Avg. Volume (3M) | 1,402,932 |
| Market Cap | 717,685,440 |
| Price / Book | 1.62 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -0.570 |
| Total Debt/Equity (MRQ) | 12.72% |
| Current Ratio (MRQ) | 12.35 |
| Operating Cash Flow (TTM) | -107.72 M |
| Levered Free Cash Flow (TTM) | -91.89 M |
| Return on Assets (TTM) | -22.16% |
| Return on Equity (TTM) | -45.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Erasca, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | -0.75 |
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.69% |
| % Held by Institutions | 84.38% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 30 Jun 2025 | 22,729,436 |
| Vr Adviser, Llc | 30 Jun 2025 | 17,857,083 |
| Logos Global Management Lp | 30 Jun 2025 | 15,000,000 |
| Suvretta Capital Management, Llc | 30 Jun 2025 | 14,502,004 |
| Paradigm Biocapital Advisors Lp | 30 Jun 2025 | 11,907,182 |
| Arch Venture Management, Llc | 30 Jun 2025 | 11,055,554 |
| Siren, L.L.C. | 30 Jun 2025 | 8,757,249 |
| Vivo Capital, Llc | 30 Jun 2025 | 6,756,756 |
| 5Am Venture Management, Llc | 30 Jun 2025 | 5,405,404 |
| Affinity Asset Advisors, Llc | 30 Jun 2025 | 4,085,787 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 4.00 (Stifel, 58.10%) | Buy |
| Median | 2.00 (-20.95%) | |
| Low | 1.00 (B of A Securities, -60.47%) | Sell |
| Average | 2.33 (-7.91%) | |
| Total | 1 Buy, 1 Hold, 1 Sell | |
| Avg. Price @ Call | 1.83 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 16 Oct 2025 | 4.00 (58.10%) | Buy | 2.53 |
| B of A Securities | 03 Sep 2025 | 1.00 (-60.47%) | Sell | 1.43 |
| Morgan Stanley | 18 Aug 2025 | 2.00 (-20.95%) | Hold | 1.53 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Sep 2025 | Announcement | Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference |
| 12 Aug 2025 | Announcement | Erasca Reports Second Quarter 2025 Business Updates and Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |